Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAVE: High-dose Ranibizumab in Refractory Wet AMD
NCT01025232Phase 2Terminated
- Sponsor
- David M. Brown
- Start
- Dec 2009
- Primary completion
- Jan 2013
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ranibizumab in exudative macular degeneration, sponsored by David M. Brown. Started Dec 2009; status: terminated.
02
Drugs
ranibizumab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT01025232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01025232.